Undisclosed HBV therapeutic / Shanghai Jinwei Biotechnology, TheraVectys - LARVOL DELTA

HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. (PubMed, Euroasian J Hepatogastroenterol) - "Aguilar JC, Akbar SMF, Al-Mahtab M, et al. HeberNasvac: Development and Application in the Context of Chronic Hepatitis B. Euroasian J Hepato-Gastroenterol 2024;14(2):221-237."

Journal • Review • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Enhanced hepatitis B virus-specific immunity by combined neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B infection. (PubMed, Hepatology) - "Although the combination therapy did not result in a functional cure, our findings indicate it produced additive effects on the development of HBV-specific T cells in the liver immediately following treatment, offering a better insight into the mechanisms underlying hepatic tolerance."

Journal • Preclinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • CD8

Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers. (PubMed, J Hepatol) - "A lentiviral-vectored therapeutic vaccine for chronic HBV infection demonstrated the potential to improve HBV-specific T cell response and deplete HBV-positive hepatocytes, leading to a sustained loss or reduction of serum HBsAg."

Journal • Preclinical • Viral vector • Hepatitis B • Hepatology • Infectious Disease • Inflammation

EFFICACY OF THERAPEUTIC VACCINATION WITH LENTIVIRAL VECTOR FOR CHRONIC HEPATITIS B IN HBV PERSISTENT MICE AND INTERIM RESULTS FOR TWO PATIENTS (AASLD 2022) - "This study demonstrates that lentiviral vectored therapeutic vaccine for chronic HBV infection can overcome HBV-specific T cell tolerance and downsize the HBV-positive hepatocytes, leading to a sustained loss or reduction in serum HBsAg. It paves the way for larger clinical studies."

Late-breaking abstract • Preclinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation